SUNNYVALE, Calif., Aug. 30 /PRNewswire/ -- Arbor Vita Corporation announced today that three abstracts featuring the company’s drug discovery and preclinical development of its HPV diagnostic and therapeutic programs have been accepted for presentation at the 23rd Papillomavirus Conference and Clinical Workshop in Prague, the Czech Republic, September 1 through 7, 2006.
Abstracts include:
“Developing a Lateral Flow Strip Test for E6 Oncoprotein to Identify Cervical Intraepithelial Neoplasia (CIN) at Increased Risk of Progression to Cervical Cancer”
This paper describes joint research with PATH (Seattle, USA) on the development of a low-cost test for cervical cancer screening for developing countries.
Presentation: 8:30 am, September 4, 2006
“High Risk HPV E6 Activates the Oncogenic JNK Pathway by Interacting with PDZ-protein MAGI1"
This paper provides strong evidence for the validation of Arbor Vita’s target for the discovery of drugs to treat cervical cancer.
Presentation: 10 am, September 4, 2006
“Detection of High Risk HPV-E6 Oncoprotein in Low and High-Grade Cervical Intraepithelial Neoplasia (CIN): Emerging Evidence for Predictive Validity”
This poster provides data demonstrating the potential for Arbor Vita’s marker for diagnosing women at risk for cervical cancer, utilizing clinical samples obtained under Arbor Vita’s collaboration with PATH.
Poster: 10 am to noon, September 6, 2006
Additional information regarding the 23rd Papillomavirus Conference and Clinical Workshop can be found at: http://www.ipvconference2006.org . Additional information about PATH, an international, nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health, can be found at: http://www.path.org .
About Arbor Vita Corporation
Arbor Vita ( www.arborvita.com ) is a biotechnology company focused on the discovery, development, and commercialization of novel drugs and diagnostics addressing disease through a new family of targets, PDZ proteins. PDZ proteins are critical elements that organize and regulate many signaling pathways in human cells. Arbor Vita is pioneering the development of therapeutics and diagnostics through their unique understanding of the role of PDZs in cell signaling and disease.
Human papillomavirus (HPV) is the principal cause of cervical cancers. The E6 protein has been identified as a cancer specific marker produced by HPV that is associated with progression to cancer. Arbor Vita is utilizing its proprietary PDZ-based proteomics platform to develop both diagnostics and therapeutics which specifically target the HPV E6 protein. In addition, the company is tackling major health issues including cancer, infectious diseases such as influenza, stroke and cardiovascular disease.
Arbor Vita Corporation
CONTACT: Debra Bannister of Arbor Vita Corporation, +1-530-676-8001
